This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
November 3–5, 2025
Vienna Congress and Convention Center, Vienna, AustriaNovember 11–12, 2025 | Digital Partnering

Janelle Anderson
CBO at F2G Limited
Speaker

Profile

Dr. Janelle R. Anderson is the Chief Business Officer of F2G. She brings 20 years of experience in operational and dealmaking roles in the biopharmaceutical industry and with venture capital funds. Prior to joining F2G, Janelle served as Chief Strategy Officer of Century Therapeutics, a company that she was instrumental in founding while an Entrepreneur-in-Residence at Versant Ventures. She drove the execution of deals and external partnerships that enabled Century's scientific and strategic objectives to be met, including securing its foundational technology and acquiring Empirica Therapeutics. Previously, while at Merck, Janelle headed Finance for Biologics and Vaccines R&D, built Merck's therapeutic-focused venture arm, MRL Ventures Fund, and served as the Managing Director. She was also a Managing Partner at CTI Life Sciences Fund, where she led US biotechnology transactions, and interim Chief Executive Officer of Access Scientific while at Carrot Capital. She currently serves as a Director on the boards of Gardiner Healthcare Acquisitions Corp and Jazz House Kids.

Janelle began her career as a management consultant at the Boston Consulting Group and is a chemist by training, having received her BSc in chemistry (honors) from McGill University, and AM and PhD from the Department of Chemistry and Chemical Biology at Harvard University.